Interest in oligonucleotide therapeutics has grown, as has the market demand, since their emergence as a new drug modality two decades ago.

The global market for oligonucleotide therapeutics is expanding rapidly. Bachem, an innovation-driven company based in Bubendorf, Switzerland, has entered this...

The global market for oligonucleotide therapeutics is expanding rapidly. Bachem, an innovation-driven company based in Bubendorf, Switzerland, has entered this...

Innovative strength has been a cornerstone of Bachem’s business success since the founding nearly 50 years ago. Günther Loidl, Chief Technology Officer for Bachem Holding...

Swiss CDMO Bachem has signed an exclusive licensing agreement to use the liquid phase peptide manufacturing technology Molecular Hiving developed by Japan’s Jitsubo.

Swiss biochemicals company Bachem announced that Dr. Anne-Kathrin Stoller will succeed Dr. José de Chastonay as Chief Marketing Officer of the organization on January 1...

Despite tremendous challenges facing the pharmaceutical industry, it continues with its commitment to innovation and the discovery of novel drugs to address unmet medical...

The folded structure of a protein defines its interactions with other molecules. Selective binding ligands could be, e.g., other proteins or peptides. A natural protein...